Received Apr 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 4MG3E | IM |
Inappropriate route of administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 36-year-old male patient who received MMR (Priorix) (batch number 4MG3E, expiry date 01-DEC-2026) for prophylaxis. On 07-APR-2026, the patient received the 1st dose of Priorix (intramuscular). On 07-APR-2026, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Inappropriate route of administration). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-APR-2026 A pharmacist reported that it was discovered that Priorix was administered intramuscularly last week (from the date of reporting) and someone else administered the vaccine.